BioSpace News Archive

The proton center at Huntsman Cancer Institute at the University of Utah will be the first in the Mountain West.

Collaboration offers clinicians a personalized oncology solution that combines cutting-edge MRI-guided radiation therapy with a leading AI-driven EMR integration platform

Centene to waive COVID-19 related costs for Medicare, Medicaid and Marketplace members, building on steps already taken in partnership with the White House Coronavirus Task Force

CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the full year ended December 31, 2019 and provided an update on the Company’s business developments

Pandion Therapeutics, Inc., a clinical-stage, privately-held biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that it has closed an $80 million Series B financing

Bruker Corporation this week highlights new analytical systems and high-value solutions for biopharma and forensics applications, as well as for industrial process control and materials science research.

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2019 and announced recent business highlights.

New Service overcomes challenges of manufacturing difficult neoantigen peptides critical to personalized cancer vaccine and T-cell therapy generation

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced that it has begun a cooperative research effort with University of Virginia Health (UVA) and the Integrated Translational Research Institute of Virginia (

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today provided an update on its business strategy and financial position in light of the current COVID-19 situation.